218 related articles for article (PubMed ID: 29907650)
1. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
[TBL] [Abstract][Full Text] [Related]
2. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
3. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Wu SC; Li LS; Kopp N; Montero J; Chapuy B; Yoda A; Christie AL; Liu H; Christodoulou A; van Bodegom D; van der Zwet J; Layer JV; Tivey T; Lane AA; Ryan JA; Ng SY; DeAngelo DJ; Stone RM; Steensma D; Wadleigh M; Harris M; Mandon E; Ebel N; Andraos R; Romanet V; Dölemeyer A; Sterker D; Zender M; Rodig SJ; Murakami M; Hofmann F; Kuo F; Eck MJ; Silverman LB; Sallan SE; Letai A; Baffert F; Vangrevelinghe E; Radimerski T; Gaul C; Weinstock DM
Cancer Cell; 2015 Jul; 28(1):29-41. PubMed ID: 26175414
[TBL] [Abstract][Full Text] [Related]
4. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.
van Bodegom D; Zhong J; Kopp N; Dutta C; Kim MS; Bird L; Weigert O; Tyner J; Pandey A; Yoda A; Weinstock DM
Blood; 2012 Oct; 120(14):2853-63. PubMed ID: 22915648
[TBL] [Abstract][Full Text] [Related]
5. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
6. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
[TBL] [Abstract][Full Text] [Related]
7. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
[TBL] [Abstract][Full Text] [Related]
9. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
10. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
11. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Weigert O; Lane AA; Bird L; Kopp N; Chapuy B; van Bodegom D; Toms AV; Marubayashi S; Christie AL; McKeown M; Paranal RM; Bradner JE; Yoda A; Gaul C; Vangrevelinghe E; Romanet V; Murakami M; Tiedt R; Ebel N; Evrot E; De Pover A; Régnier CH; Erdmann D; Hofmann F; Eck MJ; Sallan SE; Levine RL; Kung AL; Baffert F; Radimerski T; Weinstock DM
J Exp Med; 2012 Feb; 209(2):259-73. PubMed ID: 22271575
[TBL] [Abstract][Full Text] [Related]
12. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
Roll JD; Reuther GW
Cancer Res; 2010 Oct; 70(19):7347-52. PubMed ID: 20807819
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
15. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
[TBL] [Abstract][Full Text] [Related]
18. The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.
Funakoshi-Tago M; Tago K; Sumi K; Abe M; Aizu-Yokota E; Oshio T; Sonoda Y; Kasahara T
J Biol Chem; 2009 May; 284(19):12680-90. PubMed ID: 19289461
[TBL] [Abstract][Full Text] [Related]
19. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
[TBL] [Abstract][Full Text] [Related]
20. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
